Pharmaceutical composition for treating or preventing hcv infection

A composition and drug technology, applied in the direction of drug combination, antineoplastic drugs, pharmaceutical formulations, etc.
CN101489580AInactive Publication Date: 2009-07-22TOKYO METROPOLITAN INST OF MEDICAL SCI +1
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
TOKYO METROPOLITAN INST OF MEDICAL SCI
Publication Date
2009-07-22
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The inventors examined an anti-HCV effect of an SPT inhibitor and / or interferon using an HCV subgenomic replicon cell FLR3-1 or an HCV infected chimeric mouse. As a result, it was found that myriocin, an SPT inhibitor, or a compound represented by the formula (III) can be a novel therapeutic agent for HCV infection and that a higher HCV replication inhibitory effect can be obtained by concomitantly using the SPT inhibitor and interferon.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a pharmaceutical composition containing myriocin and interferon as active ingredients for treating or preventing HCV infection and its application. Background technique

[0002] Hepatitis C (HCV) infection usually leads to chronic hepatitis, often leading to cirrhosis or hepatocellular carcinoma. The number of carriers currently rises to about 3% of the world's population (-170 million people). Since HCV evades the host's immune system for unknown reasons, even when infected by adults with developed immune systems, persistent infection often occurs and progresses to chronic hepatitis, liver cirrhosis, and liver cancer. It is known that liver cancer recurs in many patients due to persistent inflammation at non-cancerous sites even after surgical removal.

[0003] Currently, the most effective treatment for HCV infection is known to be the combined use of PEGylated interferon (PEG-IFN) and ribavirin (Non-Patent Documents 1 and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More